Earnings History Data for Sanofi (SNY) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Sanofi

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
25-07-2024	PM		SNY	Sanofi	127,570	0.93	0.88	0.95	Sanofi Non-GAAP EPS of €1.73, revenue of €10.74B; raises FY24 EPS outlook [7/25/2024 1:53 AM]	53.19	1.99 (3.89%)	52.70	1.50 (2.93%)	42.63 - 55.72	4,052,112	2,000,000	394,763
Sanofi Non-GAAP EPS of €1.73, revenue of €10.74B; raises FY24 EPS outlook [7/25/2024 1:53 AM] Sanofi ending development of mid-stage dwarfism therapy [7/25/2024 2:00 PM]
25-04-2024	PM		SNY	Sanofi	120,640	0.96	0.96	1.16	Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance [4/25/2024 1:38 AM]	49.35	2.74 (5.89%)	48.87	2.26 (4.85%)	42.63 - 57.82	5,750,419	2,300,000	242,364
Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance [4/25/2024 1:38 AM]
01-02-2024	PM		SNY	Sanofi	126,790	0.89	0.94	0.87	Sanofi Non-GAAP EPS of €1.66, revenue of €10.92B; initiates FY24 outlook [2/1/2024 1:38 AM]	48.38	-1.52 (-3.04%)	48.55	-1.35 (-2.71%)	42.63 - 57.82	2,831,261	1,920,000	79,758
Sanofi Non-GAAP EPS of €1.66, revenue of €10.92B; initiates FY24 outlook [2/1/2024 1:38 AM] Sanofi incurs loss in Q4 amid generic competition, currency woes [2/1/2024 7:03 AM] Sanofi proposes annual dividend of €3.76 [2/1/2024 7:55 AM]
27-10-2023	PM		SNY	Sanofi	131,960	1.39	1.37	1.45	Sanofi Non-GAAP EPS of €2.55, revenue of €11.96B; reaffirms FY23 outlook [10/27/2023 1:41 AM]	43.14	-10.19 (-19.11%)	44.62	-8.71 (-16.33%)	41.54 - 57.82	11,376,356	1,850,000	3,957,413
Sanofi Non-GAAP EPS of €2.55, revenue of €11.96B; reaffirms FY23 outlook [10/27/2023 1:41 AM] Sanofi stock dips on plans to spin off consumer healthcare unit [10/27/2023 6:01 AM] Sanofi shares hit 52-week low amid downwardly revised forecast [10/27/2023 12:55 PM]
28-07-2023	PM		SNY	Sanofi	134,930	0.95	0.88	0.92	Sanofi Non-GAAP EPS of €1.74, revenue of €9.96B; raises FY23 guidance [7/28/2023 2:01 AM]	52.48	-1.06 (-1.99%)	51.97	-1.57 (-2.93%)	36.91 - 57.82	3,015,663	1,170,000	37,150
Sanofi Non-GAAP EPS of €1.74, revenue of €9.96B; raises FY23 guidance [7/28/2023 2:01 AM] Sanofi to grow 'healthy aging' segment with Qunol acquisition [7/28/2023 6:08 AM]
27-04-2023	PM	0:00 AM ET (Apr 27)	SNY	Sanofi	142,810	1.16	1.10	1.09	Sanofi reports mixed Q1 earnings; reaffirms FY23 outlook [4/27/2023 1:35 AM]	56.09	-0.13 (-0.24%)	55.81	-0.41 (-0.73%)	36.91 - 57.82	1,496,251	1,660,000	155,026
Sanofi reports mixed Q1 earnings; reaffirms FY23 outlook [4/27/2023 1:35 AM] Provention Bio gains after HSR waiting period for Sanofi deal expired [4/26/2023 9:11 AM] Sanofi Q1 profit climbs on Dupixent as drug on track for €10B this year [4/27/2023 6:08 AM] Sanofi completes Provention Bio acquisition [4/27/2023 10:03 AM]
03-02-2023	PM	0:00 AM ET (Feb 3)	SNY	Sanofi	122,130	0.87	0.90	0.79	Sanofi Non-GAAP EPS of €1.71 in-line, revenue of €10.72B misses by €260M; initiates FY23 guidance [2/3/2023 1:38 AM]	46.06	-1.18 (-2.50%)	45.78	-1.46 (-3.09%)	36.91 - 57.79	2,768,972	2,010,000	562,234
Sanofi Non-GAAP EPS of €1.71 in-line, revenue of €10.72B misses by €260M; initiates FY23 guidance [2/3/2023 1:38 AM] Sanofi Q4 2022 Earnings Preview [2/2/2023 11:03 AM] Sanofi stock dips as Q4 revenue grows but vaccine sales fall; Dupixent drives moderate profit outlook [2/3/2023 5:13 AM] Sanofi proposes annual dividend of €3.56 [2/3/2023 8:17 AM] Sanofi puts brakes on phase 3 trials of myasthenia gravis candidate tolebrutinib [2/3/2023 2:15 PM]
28-10-2022	PM		SNY	Sanofi	104,960	1.45	1.31	1.29	Sanofi reports Q3 earnings beat; raises FY22 EPS guidance [10/28/2022 1:51 AM]	43.07	1.49 (3.58%)	42.79	1.21 (2.91%)	36.91 - 57.79	2,856,367	3,410,000	132,644
Sanofi reports Q3 earnings beat; raises FY22 EPS guidance [10/28/2022 1:51 AM] Sanofi Q3 2022 Earnings Preview [10/27/2022 2:44 PM] Sanofi Q3 sales boosted by Dupixent, Vaccines business; raises FY22 outlook again [10/28/2022 5:09 AM] Flu season off to a strong and early start, CDC data finds [10/28/2022 12:55 PM]
28-07-2022	PM	5:00 AM ET (Jul 28)	SNY	Sanofi	124,620	0.92	0.86	0.83	Sanofi Non-GAAP EPS of€1.73, revenue of €10.17B beats estimates [7/28/2022 4:19 AM]	50.92	0.01 (0.01%)	50.28	-0.64 (-1.26%)	46.68 - 57.79	2,028,923	1,440,000	1,458
Sanofi Non-GAAP EPS of€1.73, revenue of €10.17B beats estimates [7/28/2022 4:19 AM] Sanofi raises FY22 outlook while Q2 sales boosted by blockbuster Dupixent [7/28/2022 5:05 AM] UPDATE 1-Sanofi lifts profit outlook as Dupixent sales surge 43% [Jul-28-22 02:20AM] Sanofi lifts profit outlook as Dupixent sales surge 43% [Jul-28-22 01:33AM] Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease [Jul-28-22 01:30AM] Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More [Jul-27-22 02:23PM]
28-04-2022	PM	5:00 AM ET (Apr 28)	SNY	Sanofi	134,630	1.09	0.94	0.97	Sanofi Non-GAAP EPS of $1.94 beats by €0.18, revenue of €9.67B beats by €380M; updates FY22 guidance [4/28/2022 1:52 AM]	54.34	0.0 (0.00%)	53.00	-1.34 (-2.47%)	46.92 - 58.10	2,675,506	1,900,000	4,151
Sanofi Q1 2022 Earnings Preview [4/27/2022 2:29 PM] Sanofi collaborates with McLaren Racing for manufacturing efficiency, performance [4/27/2022 5:39 AM] Sanofi Non-GAAP EPS of $1.94 beats by €0.18, revenue of €9.67B beats by €380M; updates FY22 guidance [4/28/2022 1:52 AM] Sanofi Q1 sales climb on the back of Dupixent, consumer healthcare show; maintains outlook [4/28/2022 5:19 AM] Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More [Apr-27-22 02:03PM] Should You Buy Sanofi (SNY) Ahead of Earnings? [Apr-27-22 08:42AM] UPDATE 1-Sanofi profit gain beats market view on bestseller drug Dupixent [Apr-28-22 02:02AM] Sanofi profit gain beats market view on bestseller drug Dupixent [Apr-28-22 01:32AM] Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 [Apr-28-22 01:30AM] UPDATE 2-Sanofi profit gain beats market view on bestseller drug Dupixent [Apr-28-22 02:02AM] Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again [Apr-28-22 08:57AM] Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise [Apr-28-22 10:52AM]
04-02-2022	PM	0:00 AM ET (Feb 4)	SNY	Sanofi	131,620	0.79	0.76	0.73	Sanofi Non-GAAP EPS of €1.38 beats by €0.02, revenue of €9.99B misses by €120M; initiates FY22 guidance [2/4/2022 1:50 AM]	52.00	-0.46 (-0.88%)	50.86	-1.60 (-3.05%)	45.17 - 54.26	2,653,665	1,700,000	94,516
Will Sanofi maintain EPS beat run in Q4 2021? [2/3/2022 10:03 AM] Sanofi Non-GAAP EPS of €1.38 beats by €0.02, revenue of €9.99B misses by €120M; initiates FY22 guidance [2/4/2022 1:50 AM] Sanofi meets earnings estimates even as vaccine business underperforms [2/4/2022 7:01 AM] Press Release: Sanofi unveils new corporate brand and logo unites the company under one purpose and a single identity [Feb-03-22 11:00AM] UPDATE 1-EU watchdog says supports fast development of Omicron-only vaccine [Feb-03-22 09:36AM] France's Sanofi eyes COVID-19 shot approval helping grow 2022 earnings [Feb-04-22 01:32AM] France's Sanofi still sees COVID-19 phase 3 trial completed in Q1 [Feb-04-22 01:32AM] Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars [Feb-04-22 06:17AM] Sanofi CFO details earnings, COVID-19 vaccine outlook, and drug development [Feb-04-22 11:46AM] Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV [Feb-04-22 10:20AM] Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth [Feb-04-22 10:03AM] COVID SCIENCE-Alzheimer's-like changes found in COVID patients' brains; flu shot, mRNA booster safe together [Feb-04-22 02:02PM] FDA approves Enjaymo (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease [Feb-04-22 05:00PM]
28-10-2021	PM	1:30 AM ET (Oct 28)	SNY	Sanofi	125,420	1.29	1.18	1.07	Sanofi EPS beats by €0.19, revenue in-line, boost FY outlook [10/28/2021 1:58 AM]	50.18	0.61 (1.23%)	49.93	0.36 (0.73%)	44.76 - 54.26	2,297,705	1,660,000	170,464
Sanofi Q3 2021 Earnings Preview [10/27/2021 3:14 PM] Sanofi EPS beats by €0.19, revenue in-line, boost FY outlook [10/28/2021 1:58 AM] Strong growth in Dupixent sales helps drive Sanofi's Q3 earnings beat [10/28/2021 7:58 AM] Sanofi: Information concerning the total number of voting rights and shares - September 2021 [Oct-27-21 02:57PM] Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More [Oct-27-21 11:10AM] Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1) [Oct-28-21 01:30AM] Sanofi Raises FY21 Earnings Outlook As Dupixent, Vaccines Boost Q3 Performance [Oct-28-21 06:58AM] Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up [Oct-28-21 10:46AM] Ability to vaccinate 5 year olds & up to be critical in aiding pandemic resolution: Doctor [Oct-28-21 02:21PM]
29-07-2021	PM	1:30 AM ET (Jul 29)	SNY	Sanofi	129,260	0.83	0.79	0.65	Sanofi EPS beats by $0.06, beats on revenue [7/29/2021 1:39 AM]	51.46	-0.60 (-1.15%)	51.64	-0.42 (-0.81%)	44.76 - 54.26	1,544,591	1,240,000	93,827
Viatris' Semglee, first interchangeable biosimilar insulin, approved by FDA [7/28/2021 6:00 PM] Sanofi Q2 2021 Earnings Preview [7/28/2021 2:55 PM] Sanofi EPS beats by $0.06, beats on revenue [7/29/2021 1:39 AM] Sanofi reports strong Q2 results driven by accelerated Dupixent and Vaccines sales; FY 2021 outlook raised [7/29/2021 6:37 AM] Covid-19 vaccine booster shots will become a reality: Doctor [Jul-28-21 01:51PM] Sanofi raises profit forecast after second quarter beat [Jul-29-21 01:39AM] Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI [Jul-29-21 01:31AM] Sales growth accelerated - Full-year guidance raised [Jul-29-21 01:30AM] Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients [Jul-29-21 01:00AM] Viatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus [Jul-29-21 08:12AM] Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients [Jul-29-21 07:06AM] Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast [Jul-29-21 07:19AM] Online availability of Sanofis half-year financial report for 2021 [Jul-29-21 12:24PM] We must move towards vaccine mandates to get ahead of Covid-19: Doctor [Jul-29-21 02:06PM] Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised [Jul-29-21 12:58PM]
28-04-2021	PM	0:00 AM ET (Apr 28)	SNY	Sanofi	129,570	0.97	0.83	0.90	Sanofi EPS beats by €0.27, beats on revenue [4/28/2021 1:33 AM]	52.58	1.02 (1.98%)	52.55	0.99 (1.92%)	44.11 - 55.00	1,840,037	1,280,000	62,181
Sanofi Q1 2021 Earnings Preview [4/27/2021 12:37 PM] GoodRx platform to provide consumers with direct access to Sanofi discount program [4/27/2021 9:51 AM] Sanofi EPS beats by €0.27, beats on revenue [4/28/2021 1:33 AM] Sanofi Q1 earnings beat driven by increases in specialty care and vaccines [4/28/2021 8:05 AM] CDCs latest guidance on outdoor mask wearing is a big milestone: Doctor [Apr-27-21 01:58PM] SoftBank Leads $525 Million Fund Raise for U.K. Pharma Startup [Apr-27-21 11:00AM] Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER [Apr-28-21 01:30AM] Eczema treatment and vaccines lift Sanofi first quarter results [Apr-28-21 03:11AM] Fed day keeps investors on the sidelines, but Deutsche Bank climbs after blowout results [Apr-28-21 04:57AM] Sanofi Beats Earnings Estimates and Reveals Covid-19 Vaccine Progress. The Stock Is Rising. [Apr-28-21 07:03AM] Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View [Apr-28-21 11:06AM] Its good to lift COVID-19 restrictions right now: UAB Epidemiologist [Apr-28-21 01:32PM] Sanofi SA (SNY) Q1 2021 Earnings Call Transcript [Apr-28-21 03:30PM] Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran [Apr-28-21 01:27PM]
05-02-2021	PM	0:00 AM ET (Feb 5)	SNY	Sanofi	118,780	0.73	0.88	0.74	Sanofi EPS beats by €0.05, misses on revenue, Dupixent sales up 44.6% [2/5/2021 1:36 AM]	48.19	1.07 (2.27%)	48.55	1.43 (3.03%)	37.62 - 55.00	3,531,273	3,400,942	577,304
Sanofi EPS beats by €0.05, misses on revenue, Dupixent sales up 44.6% [2/5/2021 1:36 AM] Sanofi Q4 2020 Earnings Preview [2/4/2021 1:19 PM] Sanofi Q4 Dupixent sales up 44%, Specialty Care sales grew 11.3% [2/5/2021 7:38 AM] Sanofi: Q4 Earnings Insights [Feb-05-21 07:57AM] Under pressure to deliver COVID shot, Sanofi seeks more cost cuts [Feb-05-21 01:42AM] Sanofi to expand cost-savings push to bolster R&D efforts [Feb-04-21 07:00PM]
29-10-2020	PM	0:00 AM ET (Oct 29)	SNY	Sanofi	119,100	1.07	1.08	1.07	Sanofi EPS beats by €0.07, misses on revenue [10/29/2020 3:03 AM]	45.51	-0.63 (-1.37%)	45.54	-0.60 (-1.30%)	37.62 - 55.00	2,114,405	1,076,743	13,355

29-07-2020	PM	0:00 AM ET (Jul 29)	SNY	Sanofi	130,850	0.65	0.69	0.74	Sanofi EPS beats by €0.06, misses on revenue [7/29/2020 1:42 AM]	52.78	0.95 (1.83%)	52.87	1.04 (2.01%)	37.62 - 55.00	751,305	898,230	28,181